

Kvalifikationer

Neurologi, Lektor, Medicinska fakulteten

2023 sep. 1 → ...

Tilldelningsdatum: 2022 sep. 1

Neurovetenskap, Docent, Medicinska fakulteten

Tilldelningsdatum: 2016 okt. 4

Klinisk Neurovetenskap, Med. Dr. , Validation of brief cognitive tests, Medicinska fakulteten

Tilldelningsdatum: 2011 juni 18

2020 → ... Specialist i Neurologi

Medical doctor, MD

Anställning

Docent, Universitetslektor

Klinisk minnesforskning

Lunds universitet

Malmö, Sverige

2007 juni 11 → present

Principal Investigator

MultiPark: Multidisciplinary research focused on Parkinson's disease

Lunds universitet

Lund, Sverige

2012 jan. 1 → present

Profilområdesmedlem

LU profilområde: Proaktivt åldrande

Lunds universitet

Sverige

2023 jan. 1 → present

Överläkare

Minnesmottagningen, Skånes universitetssjukhus, Malmö

Malmö, Sverige

2020 mars 1 → present

Leg. läkare

Skåne University Hospital

Region Skåne, Sverige

2007 jan. 1 → 2020 mars 1

Forskningsoutput

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease

Pereira, J. B., Kumar, A., Hall, S., Palmqvist, S., Stomrud, E., Bali, D., Parchi, P., Mattsson-Carlsson, N., Janelidze, S. & Hansson, O., 2023 sep. 18, (E-pub ahead of print) *l: Nature Aging*. 20 s.

Age-related and amyloid-beta-independent tau deposition and its downstream effects

Wuestefeld, A., Pichet Binette, A., Berron, D., Spotorno, N., van Westen, D., Stomrud, E., Mattsson-Carlsson, N., Strandberg, O., Smith, R., Palmqvist, S., Glenn, T., Moes, S., Honer, M., Arfanakis, K., Barnes, L. L., Bennett, D. A., Schneider, J. A., Wisse, L. E. M. & Hansson, O., 2023 aug. 1, *l: Brain : a journal of neurology*. 146, 8, s. 3192-3205 14 s.

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease

Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., Pichet Binette, A., Palmqvist, S., Sato, C., Sachdev, P., Koyama, A., Gordon, B. A., Benzinger, T. L. S., Holtzman, D. M.,

Morris, J. C., Mattsson-Carlgrén, N., & 5 andra Stomrud, E., Ossenkoppele, R., Schindler, S. E., Hansson, O. & Bateman, R. J., 2023 aug., I: *Nature Medicine*. 29, 8, s. 1954-1963 10 s.

Clinical effects of Lewy body pathology in cognitively impaired individuals

Quadalti, C., Palmqvist, S., Hall, S., Rossi, M., Mammana, A., Janelidze, S., Dellavalle, S., Mattsson-Carlgrén, N., Baiardi, S., Stomrud, E., Hansson, O. & Parchi, P., 2023 juli 18, (E-pub ahead of print) I: *Nature Medicine*.

Cognitive effects of Lewy body pathology in clinically unimpaired individuals

Palmqvist, S., Rossi, M., Hall, S., Quadalti, C., Mattsson-Carlgrén, N., Dellavalle, S., Tideman, P., Pereira, J. B., Nilsson, M. H., Mammana, A., Janelidze, S., Baiardi, S., Stomrud, E., Parchi, P. & Hansson, O., 2023 juli 18, (E-pub ahead of print) I: *Nature Medicine*.

Associations of CSF PDGFR β With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes

Cicognola, C., Mattsson-Carlgrén, N., van Westen, D., Zetterberg, H., Blennow, K., Palmqvist, S., Ahmadi, K., Strandberg, O., Stomrud, E., Janelidze, S. & Hansson, O., 2023 maj 3, I: *Neurology*. 101, 1, s. E30-E39

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia

Gertje, E. C., Janelidze, S., van Westen, D., Cullen, N., Stomrud, E., Palmqvist, S., Hansson, O. & Mattsson-Carlgrén, N., 2023 apr., I: *Neurology*. 100, 17, s. E1812-E1824

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals

Groot, C., Smith, R., Stomrud, E., Binette, A. P., Leuzy, A., Wuestefeld, A., Wisse, L. E. M., Palmqvist, S., Mattsson-Carlgrén, N., Janelidze, S., Strandberg, O., Ossenkoppele, R. & Hansson, O., 2023 apr., I: *Brain : a journal of neurology*. 146, 4, s. 1580-1591 12 s.

Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period

Glans, I., Sonestedt, E., Nägga, K., Gustavsson, A-M., González-Padilla, E., Borné, Y., Stomrud, E., Melander, O., Nilsson, P., Palmqvist, S. & Hansson, O., 2023 jan. 3, I: *Neurology*. 100, 1, s. e28-e37

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

Leuzy, A., Binette, A. P., Vogel, J. W., Klein, G., Borroni, E., Tonietto, M., Strandberg, O., Mattsson-Carlgrén, N., Palmqvist, S., Pontecorvo, M. J., Iaccarino, L., Stomrud, E., Ossenkoppele, R., Smith, R. & Hansson, O., 2023, I: *JAMA Neurology*. 80, 6, s. 614-623 10 s.

Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease

Pascoal, T. A., Leuzy, A., Therriault, J., Chamoun, M., Lussier, F., Tissot, C., Strandberg, O., Palmqvist, S., Stomrud, E., Ferreira, P. C. L., Ferrari-Souza, J. P., Smith, R., Benedet, A. L., Gauthier, S., Hansson, O. & Rosa-Neto, P., 2023, I: *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 15, 1, e12390.

Higher plasma β -synuclein indicates early synaptic degeneration in Alzheimer's disease

Oeckl, P., Janelidze, S., Halbgebauer, S., Stomrud, E., Palmqvist, S., Otto, M. & Hansson, O., 2023, (Accepted/In press) I: *Alzheimer's and Dementia*.

Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study

Salvadó, G., Larsson, V., Cody, K. A., Cullen, N. C., Jonaitis, E. M., Stomrud, E., Kollmorgen, G., Wild, N., Palmqvist, S., Janelidze, S., Mattsson-Carlgrén, N., Zetterberg, H., Blennow, K., Johnson, S. C., Ossenkoppele, R. & Hansson, O., 2023, (E-pub ahead of print) I: *Alzheimer's and Dementia*.

Plasma amyloid- β 42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease

Cullen, N. C., Janelidze, S., Stomrud, E., Bateman, R. J., Palmqvist, S., Hansson, O. & Mattsson-Carlgrén, N., 2023, I: *Brain Communications*. 5, 2, fcad015.

Robustness of CSF A β 42/40 and A β 42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes

Leuzy, A., Mattsson-Carlgrén, N., Cullen, N. C., Stomrud, E., Palmqvist, S., La Joie, R., Iaccarino, L., Zetterberg, H., Rabinovici, G., Blennow, K., Janelidze, S. & Hansson, O., 2023, (E-pub ahead of print) *Alzheimer's and Dementia*.

Screening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD): Study Design and Protocol

König, A., Linz, N., Baykara, E., Tröger, J., Ritchie, C., Saunders, S., Teipel, S., Köhler, S., Sánchez-Benavides, G., Grau-Rivera, O., Gispert, J. D., Palmqvist, S., Tideman, P. & Hansson, O., 2023, (E-pub ahead of print) *Journal of Prevention of Alzheimer's Disease*.

The emerging era of staging Alzheimer's disease pathology using plasma biomarkers

Mattsson-Carlgrén, N. & Palmqvist, S., 2023, *Brain*. 146, 5, s. 1740-1742 3 s.

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy

Svenningsson, A. L., Stomrud, E., Palmqvist, S., Hansson, O. & Ossenkoppele, R., 2022 dec. 1, *Alzheimer's Research and Therapy*. 14, 1, 144.

A biomarker profile of elevated CSF p-tau with normal tau PET is associated with increased tau accumulation rates on PET in early Alzheimer's disease

Groot, C., Smith, R., Stomrud, E., Binette, A. P., Leuzy, A., Wuestefeld, A., Wisse, L. E. M., Palmqvist, S., Janelidze, S., Strandberg, O., Ossenkoppele, R. & Hansson, O., 2022 dec., *Alzheimer's and Dementia*. 18, S1, e065666.

Age-related tau-PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults

Wuestefeld, A., Berron, D., Binette, A. P., van Westen, D., Stomrud, E., Mattsson-Carlgrén, N., Strandberg, O., Smith, R., Palmqvist, S., Glenn, T., Hansson, O. & Wisse, L. E. M., 2022 dec., *Alzheimer's and Dementia*. 18, S1, e067081.

Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer

Binette, A. P., Franzmeier, N., Spotorno, N., Ewers, M., Brendel, M., Biel, D., Strandberg, O., Janelidze, S., Palmqvist, S., Mattsson-Carlgrén, N., Smith, R., Stomrud, E., Ossenkoppele, R. & Hansson, O., 2022 dec., *Alzheimer's and Dementia*. 18, S1, e065080.

Gray matter hypoperfusion is a late pathological event in the course of Alzheimer's disease

Ahmedi, K., Pereira, J. B., Berron, D., Vogel, J., Ingala, S., Strandberg, O. T., Janelidze, S., Barkhof, F., Pfeuffer, J., Knutsson, L., van Westen, D., Palmqvist, S., Mutsaerts, H. J. & Hansson, O., 2022 nov. 22, (E-pub ahead of print) *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*.

Spatial Navigation and Its Association with Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia

Tangen, G. G., Nilsson, M. H., Stomrud, E., Palmqvist, S. & Hansson, O., 2022 nov. 8, *Neurology*. 99, 19, s. E2081-E2091

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease

Pichet Binette, A., Franzmeier, N., Spotorno, N., Ewers, M., Brendel, M., Biel, D., Strandberg, O., Janelidze, S., Palmqvist, S., Mattsson-Carlgrén, N., Smith, R., Stomrud, E., Ossenkoppele, R., Hansson, O. & Alzheimer's Disease Neuroimaging Initiative, 2022 nov. 4, *Nature Communications*. 13, 1, s. 6635 1 s.

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., Johnson, K., Sperling, R., Dore, V., Masters, C. L., Rowe, C., Visser, D., van Berckel, B. N. M., van der Flier, W. M., Baker, S., Jagust, W. J., & 4 andraWiste, H. J., Petersen, R. C., Jack, C. R. & Hansson, O., 2022 nov., *Nature Medicine*. 28, 11, s. 2381-2387 7 s.

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials

Borland, E., Edgar, C., Stomrud, E., Cullen, N., Hansson, O. & Palmqvist, S., 2022 sep. 13, I: *Neurology*. 99, 11, s. E1142-E1153

Association of β -Amyloid Accumulation with Executive Function in Adults with Unimpaired Cognition

Tideman, P., Stomrud, E., Leuzy, A., Mattsson-Carlgrén, N., Palmqvist, S. & Hansson, O., 2022 apr. 12, I: *Neurology*. 98, 15, s. E1525-E1533

Association of CSF $A\beta_{38}$ Levels with Risk of Alzheimer Disease-Related Decline

Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson-Carlgrén, N. & Hansson, O., 2022 mars 1, I: *Neurology*. 98, 9, s. E958-E967

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., Ossenkoppele, R., Palmqvist, S., Mattsson-Carlgrén, N., Klein, G., Stomrud, E. & Hansson, O., 2022 feb., I: *JAMA Neurology*. 79, 2, s. 149-158 10 s.

Components of gait in people with and without mild cognitive impairment

Lindh-Rengifo, M., Jonasson, S. B., Ullen, S., Stomrud, E., Palmqvist, S., Mattsson-Carlgrén, N., Hansson, O. & Nilsson, M. H., 2022 jan. 17, I: *Gait & Posture*. 93, s. 83-89

Blood-based biomarkers for Alzheimer's disease

Leuzy, A., Mattsson-Carlgrén, N., Palmqvist, S., Janelidze, S., Dage, J. L. & Hansson, O., 2022 jan., I: *EMBO Molecular Medicine*. 14, 1, e14408.

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease

Palmqvist, S., Stomrud, E., Cullen, N., Janelidze, S., Manuilova, E., Jethwa, A., Bittner, T., Eichenlaub, U., Suridjan, I., Kollmorgen, G., Riepe, M., von Arnim, C. A. F., Tuman, H., Hager, K., Heidenreich, F., Mattsson-Carlgrén, N., Zetterberg, H., Blennow, K. & Hansson, O., 2022, (Accepted/In press) I: *Alzheimer's and Dementia*.

Astrocytic function is associated with both amyloid- β and tau pathology in non-demented APOE 4 carriers

Spotorno, N., Najac, C. D. S., Stomrud, E., Mattsson-Carlgrén, N., Palmqvist, S., Van Westen, D., Ronen, I. & Hansson, O., 2022, I: *Brain Communications*. 4, 3, fcac135.

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients

Pichet Binette, A., Palmqvist, S., Bali, D., Farrar, G., Buckley, C. J., Wolk, D. A., Zetterberg, H., Blennow, K., Janelidze, S. & Hansson, O., 2022, I: *Alzheimer's Research and Therapy*. 14, 1, 46.

Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network

Pavlik, V. N., Burnham, S. C., Kass, J. S., Helmer, C., Palmqvist, S., Vassilaki, M., Dartigues, J. F., Hansson, O., Masters, C. L., Pérès, K., Petersen, R. C., Stomrud, E., Butler, L., Coloma, P. M., Teitsma, X. M., Doody, R. & Sano, M., 2022, I: *Journal of Alzheimer's Disease*. 85, 1, s. 31-45 15 s.

CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers

Ayton, S., Janelidze, S., Kalinowski, P., Palmqvist, S., Belaidi, A. A., Stomrud, E., Roberts, A., Roberts, B., Hansson, O. & Bush, A. I., 2022, (E-pub ahead of print) I: *Journal of Neurology, Neurosurgery and Psychiatry*. 330052.

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma $A\beta_{42}/A\beta_{40}$ and p-tau

Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., Teunissen, C. E., Dage, J. L., Blennow, K., Mattsson-Carlgrén, N. & Hansson, O., 2022, I: *Alzheimer's and Dementia*. 18, 2, s. 283-293

Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline

Johansson, M., Stomrud, E., Johansson, P. M., Svenningsson, A. L., Palmqvist, S., Janelidze, S., van Westen, D., Mattsson-Carlgrén, N. & Hansson, O., 2022, I: *Biological Psychiatry*. 92, 1, s. 34-43

Differential roles of A β 42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring

Ashton, N. J., Janelidze, S., Mattsson-Carlgrén, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., Jonaitis, E. M., Kosciak, R. L., Cody, K., Betthausen, T. J., Li, Y., Vanmechelen, E., Palmqvist, S., Stomrud, E., Bateman, R. J., Zetterberg, H., & 3 andraJohnson, S. C., Blennow, K. & Hansson, O., 2022, I: *Nature Medicine*. 28, 12, s. 2555-2562 8 s.

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology

Pereira, J. B., Janelidze, S., Strandberg, O., Whelan, C. D., Zetterberg, H., Blennow, K., Palmqvist, S., Stomrud, E., Mattsson-Carlgrén, N. & Hansson, O., 2022, I: *Nature Aging*. 2, 12, s. 1138-1144 7 s.

Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients

Smith, R., Cullen, N. C., Pichet Binette, A., Leuzy, A., Blennow, K., Zetterberg, H., Klein, G., Borroni, E., Ossenkoppele, R., Janelidze, S., Palmqvist, S., Mattsson-Carlgrén, N., Stomrud, E., Hansson, O. & Alzheimer's Disease Neuroimaging Initiative, 2022, (Accepted/In press) I: *Alzheimer's and Dementia*.

Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models

Cullen, N. C., Janelidze, S., Mattsson-Carlgrén, N., Palmqvist, S., Bittner, T., Suridjan, I., Jethwa, A., Kollmorgen, G., Brum, W. S., Zetterberg, H., Blennow, K., Stomrud, E. & Hansson, O., 2022, (Accepted/In press) I: *Alzheimer's and Dementia*.

The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders

Ayton, S., Hall, S., Janelidze, S., Kalinowski, P., Palmqvist, S., Belaidi, A. A., Roberts, B., Roberts, A., Stomrud, E., Bush, A. I. & Hansson, O., 2022, I: *Movement Disorders*. 37, 5, s. 993-1003

β -Amyloid-Dependent and-Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease

Kumar, A., Janelidze, S., Stomrud, E., Palmqvist, S., Hansson, O. & Mattsson-Carlgrén, N., 2022, I: *Neurology*. 99, 5, s. E476-E487

Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation

Kumar, A., Janelidze, S., Shoai, M., Palmqvist, S., Stomrud, E., Hardy, J., Hansson, O. & Mattsson-Carlgrén, N., 2021 dec., I: *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 17, e053556.

Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

Cullen, N. C., Leuzy, A., Janelidze, S., Palmqvist, S., Svenningsson, A. L., Stomrud, E., Dage, J. L., Mattsson-Carlgrén, N. & Hansson, O., 2021 dec., I: *Nature Communications*. 12, 1, 3555.

Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease

Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgrén, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K. & Hansson, O., 2021 nov., I: *Brain*. 144, 11, s. 3505-3516 12 s.

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease

Kumar, A., Shoai, M., Palmqvist, S., Stomrud, E., Hardy, J., Mattsson-Carlgrén, N. & Hansson, O., 2021 okt., I: *Scientific Reports*. 11, 1, 19853.

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory

Berron, D., Vogel, J. W., Insel, P. S., Pereira, J. B., Xie, L., Wisse, L. E. M., Yushkevich, P. A., Palmqvist, S., Mattsson-Carlgrén, N., Stomrud, E., Smith, R., Strandberg, O. & Hansson, O., 2021 sep. 1, I: *Brain*. 144, 9, s. 2771-2783 13 s.

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects

Pereira, J. B., Janelidze, S., Stomrud, E., Palmqvist, S., Van Westen, D., Dage, J. L., Mattsson-Carlgrén, N. & Hansson, O., 2021 sep., I: *Brain*. 144, 9, s. 2826-2836 11 s.

Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers

Ossenkoppele, R., Reimand, J., Smith, R., Leuzy, A., Strandberg, O., Palmqvist, S., Stomrud, E., Zetterberg, H., Scheltens, P., Dage, J. L., Bouwman, F., Blennow, K., Mattsson-Carlgrén, N., Janelidze, S., Hansson, O. & Alzheimer's Disease Neuroimaging Initiative, 2021 aug. 9, I: *EMBO Molecular Medicine*. 13, 8, e14398.

The impact of demographic, clinical, genetic, and imaging variables on tau PET status

Ossenkoppele, R., Leuzy, A., Cho, H., Sudre, C. H., Strandberg, O., Smith, R., Palmqvist, S., Mattsson-Carlgrén, N., Olsson, T., Jögi, J., Stormrud, E., Ryu, Y. H., Choi, J. Y., Boxer, A. L., Gorno-Tempini, M. L., Miller, B. L., Soleimani-Meigooni, D., Iaccarino, L., La Joie, R., Borroni, E., & 7 andraKlein, G., Pontecorvo, M. J., Devous, M. D., Villeneuve, S., Lyoo, C. H., Rabinovici, G. D. & Hansson, O., 2021 juli 1, I: *European Journal of Nuclear Medicine and Molecular Imaging*. 48, 7, s. 2245-2258 14 s.

Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

Mattsson-Carlgrén, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., Reiman, E. M., Palmqvist, S., Dage, J. L., Beach, T. G. & Hansson, O., 2021 juni 7, I: *EMBO Molecular Medicine*. 13, 6, e14022.

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

Alzheimer's Disease Neuroimaging Initiative, 2021 juni 1, I: *Nature Medicine*. 27, 6, s. 1034–1042 9 s.

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease

Johansson, M., Stomrud, E., Insel, P. S., Leuzy, A., Johansson, P. M., Smith, R., Ismail, Z., Janelidze, S., Palmqvist, S., van Westen, D., Mattsson-Carlgrén, N. & Hansson, O., 2021 jan. 26, I: *Translational Psychiatry*. 11, 1, 76.

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations

Cullen, N. C., Leuzy, A., Palmqvist, S., Janelidze, S., Stomrud, E., Pesini, P., Sarasa, L., Allué, J. A., Proctor, N. K., Zetterberg, H., Dage, J. L., Blennow, K., Mattsson-Carlgrén, N. & Hansson, O., 2021 jan., I: *Nature Aging*. 1, s. 114-123 10 s.

Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ϵ 4, sex and age

Ayton, S., Janelidze, S., Roberts, B., Palmqvist, S., Kalinowski, P., Diouf, I., Belaidi, A. A., Stomrud, E., Bush, A. I. & Hansson, O., 2021, I: *Progress in Neurobiology*. 198, 101904.

A multicentre validation study of the diagnostic value of plasma neurofilament light

Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., Galimberti, D., Bonanni, L., Pilotto, A., Padovani, A., Lycke, J., Novakova, L., Axelsson, M., Velayudhan, L., Rabinovici, G. D., Miller, B., & 21 andraPariante, C., Nikkheslat, N., Resnick, S. M., Thambisetty, M., Schöll, M., Fernández-Eulate, G., Gil-Bea, F. J., López de Munain, A., Al-Chalabi, A., Rosa-Neto, P., Strydom, A., Svenningsson, P., Stomrud, E., Santillo, A., Aarsland, D., van Swieten, J. C., Palmqvist, S., Zetterberg, H., Blennow, K., Hye, A. & Hansson, O., 2021, I: *Nature Communications*. 12, s. 1-12 3400.

Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease

Janelidze, S., Berron, D., Smith, R., Strandberg, O., Proctor, N. K., Dage, J. L., Stomrud, E., Palmqvist, S., Mattsson-Carlgrén, N. & Hansson, O., 2021, I: *JAMA Neurology*. 78, 2, s. 149

Biomarker testing in MCI patients—deciding who to test

van Maurik, I. S., Rhodius-Meester, H. F. M., Teunissen, C. E., Scheltens, P., Barkhof, F., Palmqvist, S., Hansson, O., van der Flier, W. M. & Barkhof, J., 2021, I: *Alzheimer's Research and Therapy*. 13, 1, 14.

Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays

Leuzy, A., Janelidze, S., Mattsson-Carlgrén, N., Palmqvist, S., Jacobs, D., Cicognola, C., Stomrud, E., Vanmechelen, E., Dage, J. L. & Hansson, O., 2021, *I: Neurology*. 97, 17, s. e1681-e1694

Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment

Kumar, A., Shoai, M., Palmqvist, S., Stomrud, E., Hardy, J., Mattsson-Carlgrén, N. & Hansson, O., 2021, *I: Alzheimer's & dementia : the journal of the Alzheimer's Association*. 17, e053474.

Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study

Gustavsson, A., Raket, L. L., Lilja, M., Rutten-Jacobs, L., Fues Wahl, H., Bagijn, M., Stomrud, E., Hansson, O. & Palmqvist, S., 2021, *I: Alzheimer's and Dementia*. 17, 11, s. 1832-1842

Spatial Distribution of Tau and β -Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes

Palmqvist, S. & Eshaghi, A., 2021, *I: Neurology*. 96, 5, s. 191-192 2 s.

The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people

Nilsson, M. H., Tangen, G. G., Palmqvist, S., van Westen, D., Mattsson-Carlgrén, N., Stomrud, E. & Hansson, O., 2021, *I: Journals of Gerontology. Series A: Biological Sciences & Medical Sciences*. 76, 4, s. 683-691

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., Mattsson-Carlgrén, N., Strandberg, O., Smith, R., Villegas, A., Sepulveda-Falla, D., Chai, X., Proctor, N. K., Beach, T. G., Blennow, K., Dage, J. L., & 2 andraReiman, E. M. & Hansson, O., 2020 aug. 25, *I: JAMA - Journal of the American Medical Association*. 324, 8, s. 772-781 10 s.

Mild to Moderate Cognitive Impairment Does Not Affect the Ability to Self-Report Important Symptoms in Patients With Cancer: A Prospective Longitudinal Multinational Study (EPCCS)

Ekström, M. P., Palmqvist, S., Currow, D. C., Sjøgren, P., Kurita, G. P., Jakobsen, G., Kaasa, S. & Hjermstad, M., 2020 aug. 1, *I: Journal of Pain and Symptom Management*. 60, 2, s. 346-354.e2

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders

Leuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgrén, N., Strandberg, O., Stomrud, E. & Hansson, O., 2020 aug., *I: JAMA Neurology*. 77, 8, s. 955-965 11 s.

Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline

Petrazzuoli, F., Vestberg, S., Midlöv, P., Thulesius, H., Stomrud, E. & Palmqvist, S., 2020 juni, *I: Journal of Alzheimer's disease : JAD*. 75, 4, s. 1191-1201 11 s.

The implications of different approaches to define AT(N) in Alzheimer disease

Mattsson-Carlgrén, N., Leuzy, A., Janelidze, S., Palmqvist, S., Stomrud, E., Strandberg, O., Smith, R. & Hansson, O., 2020 maj 26, *I: Neurology*. 94, 21, s. e2233-e2244 13 s.

Assessment of Demographic, Genetic, and Imaging Variables Associated with Brain Resilience and Cognitive Resilience to Pathological Tau in Patients with Alzheimer Disease

Ossenkoppele, R., Lyoo, C. H., Jester-Broms, J., Sudre, C. H., Cho, H., Ryu, Y. H., Choi, J. Y., Smith, R., Strandberg, O., Palmqvist, S., Kramer, J., Boxer, A. L., Gorno-Tempini, M. L., Miller, B. L., La Joie, R., Rabinovici, G. D. & Hansson, O., 2020 maj, *I: JAMA Neurology*. 77, 5, s. 632-642 11 s.

The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment

Borland, E., Stomrud, E., van Westen, D., Hansson, O. & Palmqvist, S., 2020 mars 24, *I: Alzheimer's Research & Therapy*. 12, 1, 30.

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., Blennow, K., Reiman, E. M., Stomrud, E., Dage, J. L. & Hansson, O., 2020 mars 2, I: Nature Medicine. 26, 3, s. 379-386 8 s.

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease

Ossenkoppele, R., Lyoo, C. H., Sudre, C. H., van Westen, D., Cho, H., Ryu, Y. H., Choi, J. Y., Smith, R., Strandberg, O., Palmqvist, S., Westman, E., Tsai, R., Kramer, J., Boxer, A. L., Gorno-Tempini, M. L., La Joie, R., Miller, B. L., Rabinovici, G. D. & Hansson, O., 2020 feb., I: Alzheimer's and Dementia. 16, 2, s. 335-344 10 s.

A β deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease

Mattsson-Carlgrén, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., Blennow, K., Dage, J. L., Stomrud, E., Smith, R., Palmqvist, S. & Hansson, O., 2020, I: Science Advances. 6, 16, eaaz2387.

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Theriault, J., Schöll, M., Massarweh, G., Soucy, J. P., Höglund, K., Brinkmalm, G., Mattsson, N., Palmqvist, S., Gauthier, S., Stomrud, E., Zetterberg, H., & 3 andraHansson, O., Rosa-Neto, P. & Blennow, K., 2020, I: The Lancet Neurology. 19, 5, s. 422-433 12 s.

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., Triana-Baltzer, G., Theunis, C., Slemmon, R., Mercken, M., Kolb, H., Dage, J. L. & Hansson, O., 2020, I: Nature Communications. 11, 1, 1683.

Coping Styles among People with Parkinson's Disease: A Three-Year Follow-Up Study

Nilsson, M. H., Oswald, F., Palmqvist, S. & Slaug, B., 2020, I: Behavioral Sciences. 10, 12, 190.

Derivation and utility of an A β -PET pathology accumulation index to estimate A β load

Leuzy, A., Lilja, J., Buckley, C. J., Ossenkoppele, R., Palmqvist, S., Battle, M., Farrar, G., Thal, D. R., Janelidze, S., Stomrud, E., Strandberg, O., Smith, R. & Hansson, O., 2020, I: Neurology. 95, 21, s. e2834-e2844

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Mattsson-Carlgrén, N., Palmqvist, S., Blennow, K. & Hansson, O., 2020, I: Nature Communications. 11, 1, 6252.

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease

Mattsson-Carlgrén, N., Janelidze, S., Palmqvist, S., Cullen, N., Svenningsson, A. L., Strandberg, O., Mengel, D., Walsh, D. M., Stomrud, E., Dage, J. L. & Hansson, O., 2020, I: Brain : a journal of neurology. 143, 11, s. 3234-3241 8 s.

Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up

Mårtensson, G., Håkansson, C., Pereira, J. B., Palmqvist, S., Hansson, O., van Westen, D. & Westman, E., 2020, I: NeuroImage: Clinical. 27, 102310.

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects

Smith, R., Strandberg, O., Mattsson-Carlgrén, N., Leuzy, A., Palmqvist, S., Pontecorvo, M. J., Devous, M. D., Ossenkoppele, R. & Hansson, O., 2020, I: Brain. 143, 12, s. 3805-3815 11 s.

Unburdening dementia: a basic social process grounded theory based on a primary care physician survey from 25 countries

Petrazzuoli, F., Vinker, S., Palmqvist, S., Midlöv, P., Lepeleire, J. D., Pirani, A., Frese, T., Buono, N., Ahrensberg, J., Asenova, R., Boreu, Q. F., Peker, G. C., Collins, C., Hanževački, M., Hoffmann, K., Iftode, C., Koskela, T. H., Kurpas, D., Reste, J. Y. L., Lichtwarck, B., & 9 andraPetek, D., Schrans, D., Soler, J. K., Streit, S., Tatsioni, A., Torzsa, P., Unalan, P.

C., Marwijk, H. V. & Thulesius, H., 2020, I: Scandinavian Journal of Primary Health Care. 38, 3, s. 253-264 12 s.

Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume

Caldwell, J. Z. K., Cummings, J. L., Banks, S. J., Palmqvist, S. & Hansson, O., 2019 dec. 26, I: Alzheimer's Research & Therapy. 11, 1, 109.

Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity

Pereira, J. B., Ossenkoppele, R., Palmqvist, S., Strandberg, T. O., Smith, R., Westman, E. & Hansson, O., 2019 dec. 9, I: eLife. 8, e50830.

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., Mattsson, N. & Hansson, O., 2019 dec. 1, I: EMBO Molecular Medicine. 11, 12, e11170.

A quick test of cognitive speed can predict development of dementia in Parkinson's disease

Jalakas, M., Palmqvist, S., Hall, S., Svärd, D., Lindberg, O., Pereira, J. B., van Westen, D. & Hansson, O., 2019 okt., I: Scientific Reports. 9, 1, 15417.

β -amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly

Svenningsson, A. L., Stomrud, E., Insel, P. S., Mattsson, N., Palmqvist, S. & Hansson, O., 2019 aug. 1, I: Scientific Reports. 9, 1, 11180.

Determining clinically meaningful decline in preclinical Alzheimer disease

Insel, P. S., Weiner, M., Mackin, R. S., Mormino, E., Lim, Y. Y., Stomrud, E., Palmqvist, S., Masters, C. L., Maruff, P. T., Hansson, O. & Mattsson, N., 2019 juli 23, I: Neurology. 93, 4, s. e322-e333

Associations between tau, A β , and cortical thickness with cognition in Alzheimer disease

Ossenkoppele, R., Smith, R., Ohlsson, T., Strandberg, O., Mattsson, N., Insel, P. S., Palmqvist, S. & Hansson, O., 2019 feb. 9, I: Neurology. 92, 6, s. e601-e612

Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study

Voevodskaya, O., Poulakis, K., Sundgren, P., Westen, D. V., Palmqvist, S., Wahlund, L. O., Stomrud, E., Hansson, O. & Westman, E., 2019 jan. 29, I: Neurology. 92, 5, s. E395-E405

Accurate risk estimation of β -amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms

Palmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Mattsson, N., Hansson, O., Alzheimer's Disease Neuroimaging Initiative & The Swedish BioFINDER study, 2019, I: Alzheimer's and Dementia. 15, 2, s. 194-204

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly

Hahn, A., Strandberg, T. O., Stomrud, E., Nilsson, M., van Westen, D., Palmqvist, S., Ossenkoppele, R. & Hansson, O., 2019, I: Cerebral Cortex. 29, s. 2173-2182

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

van Maurik, I. S., Vos, S. J., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Barkhof, F., Frolich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., R  ther, E., Nobili, F., Frisoni, G. B., Spuru, L., Freund-Levi, Y., Wallin, A. K., Hampel, H., Soininen, H., & 20 andraTsolaki, M., Verhey, F., Kłoszewska, I., Mecocci, P., Vellas, B., Lovestone, S., Galluzzi, S., Herukka, S. K., Santana, I., Baldeiras, I., de Mendonça, A., Silva, D., Chetelat, G., Egret, S., Palmqvist, S., Hansson, O., Visser, P. J., Barkhof, J., van der Flier, W. M. & Alzheimer's Disease Neuroimaging Initiative, 2019, I: The Lancet Neurology. 18, 11, s. 1034-1044 11 s.

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β -Amyloid Status

Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K. & Hansson, O., 2019, I: JAMA Neurology. 76, 9, s. 1060-1069

Relating Experienced To Recalled breathlessness Observational (RETRO) study: A prospective study using a mobile phone application

Sandberg, J., Lansing, R., Anderberg, P., Currow, D., Sundh, J., Ahmadi, Z., Palmqvist, S. & Ekström, M., 2019, I: *BMJ Open Respiratory Research*. 6, 1, e000370.

Staging β -Amyloid Pathology with Amyloid Positron Emission Tomography

Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J. & Hansson, O., 2019, I: *JAMA Neurology*. 76, 11, s. 1319-1329 11 s.

Effects of APOE ϵ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease

Mattsson, N., Eriksson, O., Lindberg, O., Schöll, M., Lampinen, B., Nilsson, M., Insel, P. S., Lautner, R., Strandberg, O., van Westen, D., Zetterberg, H., Blennow, K., Palmqvist, S., Stomrud, E. & Hansson, O., 2018 nov. 1, I: *Neurobiology of Aging*. 71, s. 81-90 10 s.

Discriminative accuracy of [18 F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders

Ossenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Scholl, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., Ohlsson, T., Jögi, J., Tsai, R., La Joie, R., Kramer, J., Boxer, A. L., Gorno-Tempini, M. L., Miller, B. L., Choi, J. Y., Ryu, Y. H., &andraLyyo, C. H. & Hansson, O., 2018 sep. 18, I: *JAMA - Journal of the American Medical Association*. 320, 11, s. 1151-1162 12 s.

Greater tau load and reduced cortical thickness in APOE ϵ 4-negative Alzheimer's disease: a cohort study

Mattsson, N., Ossenkoppele, R., Smith, R., Strandberg, O., Ohlsson, T., Jögi, J., Palmqvist, S., Stomrud, E. & Hansson, O., 2018 aug. 7, I: *Alzheimer's Research and Therapy*. 10, 1, 45.

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease

Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K. & Hansson, O., 2018 juli 27, I: *Neurology*. 91, 9, s. e867-e877

Comparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease

Mattsson, N., Smith, R., Strandberg, O., Palmqvist, S., Schöll, M., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Blennow, K., Jögi, J. & Hansson, O., 2018 jan. 30, I: *Neurology*. 90, 5, s. e388-e395

Amyloid network topology characterizes the progression of Alzheimer's disease during the prodementia stages

Pereira, J. B., Strandberg, T. O., Palmqvist, S., Volpe, G., Van Westen, D., Westman, E. & Hansson, O., 2018 jan. 1, I: *Cerebral Cortex*. 28, 1, s. 340-349 10 s.

Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people

Hansson, O., Palmqvist, S., Ljung, H., Cronberg, T., van Westen, D. & Smith, R., 2018, I: *Alzheimer's and Dementia*. 14, 1, s. 54-61

Earliest accumulation of β -amyloid occurs within the default-mode network and concurrently affects brain connectivity

Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W. & Hansson, O., 2017 dec. 1, I: *Nature Communications*. 8, 1, 1214.

Atrophy of the posterior subiculum is associated with memory impairment, Tau- and A β pathology in non-demented individuals

Lindberg, O., Mårtensson, G., Stomrud, E., Palmqvist, S., Wahlund, L. O., Westman, E. & Hansson, O., 2017 sep. 20, I: *Frontiers in Aging Neuroscience*. 9, SEP, 306.

Distinct 18 F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease

Schöll, M., Ossenkoppele, R., Strandberg, O., Palmqvist, S., Jögi, J., Ohlsson, T., Smith, R., Hansson, O. & The Swedish BioFINDER study, 2017 sep. 1, I: *Brain*. 140, 9, s. 2286-2294 9 s.

¹⁸F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease

Mattsson, N., Schöll, M., Strandberg, O., Smith, R., Palmqvist, S., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Jögi, J., Blennow, K. & Hansson, O., 2017, I: EMBO Molecular Medicine. 9, s. 1212-1223

Svenska gränsvärden för bedömning av kognitiv nedsättning framtagna

Borland, E. & Palmqvist, S., 2017, I: Läkartidningen. 114, 45, s. 1883 1 s.

The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort

Borland, E., Nägga, K., Nilsson, P. M., Minthon, L., Nilsson, E. D. & Palmqvist, S., 2017, I: Journal of Alzheimer's Disease. 59, 3, s. 893-901 9 s.

Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?

Palmqvist, S., Mattsson, N. & Hansson, O., 2016 nov. 1, I: Brain. 139, 11, s. e61

Plasma tau in Alzheimer disease

Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., Hanlon, D., Song, L., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Hansson, O. & Blennow, K., 2016 okt. 25, I: Neurology. 87, 17, s. 1827-1835 9 s.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Mattsson, N., Insel, P. S., Palmqvist, S., Portelius, E., Zetterberg, H., Weiner, M., Blennow, K. & Hansson, O., 2016 okt. 1, I: EMBO Molecular Medicine. 8, 10, s. 1184-1196 13 s.

Plasma β -amyloid in Alzheimer's disease and vascular disease

Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., Van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., Blennow, K. & Hansson, O., 2016 maj 31, I: Scientific Reports. 6, 26801.

Assessing risk for preclinical β -amyloid pathology with APOE, cognitive, and demographic information

Insel, P. S., Palmqvist, S., Mackin, R. S., Nosheny, R. L., Hansson, O., Weiner, M. W. & Mattsson, N., 2016, I: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 4, s. 76-84 9 s.

Cerebrospinal fluid analysis detects cerebral amyloid- β accumulation earlier than positron emission tomography.

Palmqvist, S., Mattsson, N. & Hansson, O., 2016, I: Brain. 139, 4, s. 1226-1236

CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease

Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., Hansson, O. & Swedish BioFINDER study group, 2016, I: Annals of Clinical and Translational Neurology. 3, 3, s. 154-65 12 s.

Increased amyloidogenic APP processing in APOE ϵ 4-negative individuals with cerebral β -amyloidosis.

Mattsson, N., Insel, P., Palmqvist, S., Stomrud, E., van Westen, D., Minthon, L., Zetterberg, H., Blennow, K. & Hansson, O., 2016, I: Nature Communications. 7, 7, 10918.

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Minthon, L., Blennow, K., Ohlsson, M., Hansson, O. & Swedish BioFINDER study group, 2015, I: Neurology. 85, 14, s. 1240-1249

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β -Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography.

Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L. & Hansson, O., 2014, I: JAMA Neurology. 71, 10, s. 1282-1289

Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease.

Lautner, R., Palmqvist, S., Mattsson, N., Andreasson, U., Wallin, A., Pålsson, E., Jakobsson, J., Herukka, S-K., Owenius, R., Olsson, B., Hampel, H., Rujescu, D., Ewers, M., Landén, M., Minthon, L., Blennow, K., Zetterberg, H. & Hansson, O., 2014, I: JAMA Psychiatry. 71, 10, s. 1183-1191

A Quick Test of Cognitive Speed: norm-referenced criteria for 121 Italian adults aged 45 to 90 years.

Petrazzuoli, F., Palmqvist, S., Thulesius, H., Buono, N., Pirrotta, E., Cuffari, A., Cambielli, M., D'Urso, M., Farinaro, C., Chiumeo, F., Marsala, V. & Wiig, E. H., 2014, I: *International Psychogeriatrics*. 26, 9, s. 1493-1500

Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study.

Nägga, K., Wattmo, C., Zhang, Y., Wahlund, L-O. & Palmqvist, S., 2014, I: *Alzheimer's Research & Therapy*. 6, 4, 41.

Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination

Londos, E., Hansson, O., Hirsch, I. A., Janneskog, A., Bülow, M. & Palmqvist, S., 2013, I: *BMC Neurology*. 13, 140.

ROI-based analysis of diffusional kurtosis estimates for identification of MCI-patients at high risk for conversion to Alzheimer's disease in a heterogeneous MCI cohort

Svärd, D., Szczepankiewicz, F., Lätt, J., Nilsson, M., Palmqvist, S., Nägga, K., Hansson, O. & van Westen, D., 2013.

Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease.

Hertze, J., Palmqvist, S., Minthon, L. & Hansson, O., 2013, I: *Dementia and Geriatric Cognitive Disorders Extra*. 3, 1, s. 113-122

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study.

Palmqvist, S., Hertze, J., Minthon, L., Wattmo, C., Zetterberg, H., Blennow, K., Londos, E. & Hansson, O., 2012, I: *PLoS ONE*. 7, 6, e38639.

Diffusion tensor tractography of the posterior cingulate gyrus and corpus callosum does not identify MCI-patients at high risk for conversion to Alzheimer's disease in a heterogeneous MCI cohort

Svärd, D., Szczepankiewicz, F., Lätt, J., Nilsson, M., Nägga, K., Palmqvist, S., Hansson, O. & van Westen, D., 2012, *Magnetic Resonance Materials in Physics, Biology and Medicine*. Suppl 1 suppl. Springer, Vol. 25. s. 378-379

Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia.

Nielsen, H., Palmqvist, S., Minthon, L., Londos, E. & Wennström, M., 2012, I: *Current Alzheimer Research*. 9, 3, s. 257-266

Association between Subcortical Lesions and Behavioral and Psychological Symptoms in Patients with Alzheimer's Disease.

Palmqvist, S., Sarwari, A., Wattmo, C., Bronge, L., Zhang, Y., Wahlund, L. O. & Nägga, K., 2011, I: *Dementia and Geriatric Cognitive Disorders*. 32, 6, s. 417-423

Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.

Johansson, C., Ballard, C., Hansson, O., Palmqvist, S., Minthon, L., Aarsland, D. & Londos, E., 2011, I: *International Journal of Geriatric Psychiatry*. 26, s. 206-213

Validation of brief cognitive tests in mild cognitive impairment, Alzheimer's disease and dementia with Lewy bodies.

Palmqvist, S., 2011, *Clinical Memory Research Unit, Lund University*. 95 s.

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease

Palmqvist, S., Minthon, L., Wattmo, C., Londos, E. & Hansson, O., 2010, I: *Alzheimer's Research & Therapy*. 2, 5, 29.

Lewykroppsdemens - stor risk för felbehandling och död

Boström, F., Palmqvist, S., Andersson, M. A. & Londos, E., 2009, I: *Läkartidningen*. 106, 20, s. 1374-1376

Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests.

Palmqvist, S., Hansson, O., Minthon, L. & Londos, E., 2009, I: International Journal of Geriatric Psychiatry. 24, s. 1405-1412

The usefulness of cube copying for evaluating treatment of Alzheimer's disease.

Palmqvist, S., Hansson, O., Minthon, L. & Londos, E., 2008, I: American Journal of Alzheimers Disease & other Dementias. 23, 5, s. 439-446

Priser och utmärkelser

Bundy Academys stora pris 2022

Palmqvist, Sebastian (Mottagare), 2022

Her Majesty Queen Silvia's Young Alzheimer's Researcher Award

Palmqvist, Sebastian (Mottagare), 2019 maj 15

Inga Sandeborgs prize

Palmqvist, Sebastian (Mottagare), 2022 aug. 30

The Bundy Academy Award in Neurology

Palmqvist, Sebastian (Mottagare), 2014

The Junior Faculty Award of the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD)

Palmqvist, Sebastian (Mottagare), 2015

Forskningsmedel

Förbättrad diagnostik av Alzheimer och kognitiv svikt i primärvården

Palmqvist, S.

Hjärnfonden: 1 200 000,00 kr

2022/07/01 → 2024/12/31

Projekt

Blood biomarkers to improve diagnostics of Alzheimer's disease and understanding of pathological and genetic pathways contributing to disease development

Orduña Dolado, A., Hansson, O., Janelidze, S., Palmqvist, S. & Mattsson-Carlsson, N.

2022/09/01 → 2026/09/01

EDAP: Early diagnostics and prognostics of Alzheimer's disease

Hansson, O., Nilsson, M. H., Johansson, M., Cutas, D., Gerdtham, U., Heyden, A., Snogerup-Linse, S., Mattsson-Carlsson, N., Palmqvist, S., Åström, K., van Westen, D. & Stomrud, E.

2021/09/01 → ...

EDAP: Early diagnostics and prognostics of Alzheimer's disease

Fawad, A., Palmqvist, S., Hansson, O. & Callingham, S.

2023/01/02 → ...

Förbättrad diagnostik av Alzheimer och kognitiv svikt i primärvården

Palmqvist, S.

Hjärnfonden, Alzheimerfonden

2018/12/01 → 2024/12/31

Predictors of future cognitive decline and neurocognitive disorders: longitudinal study of diet, demographics, plasma biomarkers and genetic risk factors in the Malmö Diet and Cancer Study

Glans, I., Palmqvist, S. & Hansson, O.

2020/12/01 → 2025/11/25

Recognition and referral of cognitive impairment in primary care-associated factors and consequences for early diagnosis and health economics

Fawad, A., Hansson, O. & Palmqvist, S.

2023/01/02 → ...

Relationen mellan hjärnpatologier, regional atrofi och kognitiva symtom vid Alzheimers sjukdom och andra neurodegenerativa sjukdomar

Svenningsson, A., Hansson, O., Palmqvist, S., Stomrud, E. & Ossenkoppele, R.

2018/08/01 → ...

The Swedish BioFINDER study

Hansson, O., Minthon, L., Stomrud, E., Palmqvist, S., Mattsson-Carlsson, N., Janelidze, S., Strandberg, O., Smith, R., Toresson, H., Schöll, M., Hall, S., Surova, Y., Johansson, M., Dahlbeck Jalakas, M., Andersson, E. & Dahl, C.

2010/01/01 → 2022/01/01